Pristiq: An Update

Pristiq (desvenlafaxine extendedrelease tablet) was approved by the FDA in February of 2008 for the treatment of major depression. In the April 2008 issue of TCPR, we reviewed the efficacy data available at that time. We concluded that it is a marginally effective antidepressant with no clear advantages over its precursor molecule, venlafaxine extended release (Effexor XR). How has Pristiq fared over the past year and half?

Current Subscribers

Purchase a subscription

To view the full content, you need to purchase a subscription.